Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age

NCT05127434 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05127434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
November 17, 2021
Completion date
July 28, 2025
Enrollment
36,814 (actual)
Sites
269

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus